Print
Email
Print Edition StoriesWednesday, July 29, 2009
Forma Therapeutics, Novartis team on cancer drugs
By Mass High Tech Staff
MHT's Marc Songini: Researchers focus on macular degeneration
MHT's Marc Songini: Mass. bio firms prep for lifting of stem cell ban
Forma Therapeutics Inc. said that it has entered into a collaboration agreement with Novartis AG to use Forma’s cell-based screening platform to discover inhibitors for undisclosed protein-protein interaction targets to help develop cancer drugs.
No financial terms of the deal were disclosed. The funding arm of pharmaceutical giant Novartis, the Novartis Option Fund, was one of the investors in Cambridge-based Forma’s $4 million funding round in March of 2008.
Earlier this month, Forma and The Leukemia & Lymphoma Society partnered in an effort to move the health agency’s research products toward development quickly. As part of the deal, Forma will help design ten small molecule drugs using its Computational Solvent Mapping technology.
In March, Forma reported it would collaborate with the Experimental Therapeutics Centre (ETC) of Singapore on development of new anti-cancer drugs. The intent is to use Forma’s transformative chemistry platform to discover new compounds that ETC will develop.
Forma Therapeutics relies on an integrated transformative biology and chemistry-based approach to develop its drugs. It uses a cell-based screening platform to permit the screening of discrete targets in cells. Headquartered in Cambridge, Forma has research operations in Connecticut, Singapore and Beijing.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
